ATKINS M SHAN sold $3K of CGC

ATKINS M SHAN sold 3,096 shares of Canopy Growth Corp (CGC) at $0.93 on 2026-09-28.

Original reporting
SEC EDGAR · ATKINS M SHAN
Published Sep 30, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
high confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The disclosed sale is minor and unlikely to affect CGC's price, but it adds to the cumulative insider activity record.

02

Market read

Low relevance; a small insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 3/10Novelty 3/10Timing: filing after market close on 2026-09-30

Background

Form 4 filings disclose insider transactions; directors' sales are monitored for potential red flags.

Company-level read

Ticker impact

$CGCNeutralHigh confidence
Context

Director M. Shan Atkins sold 3,096 shares of Canopy Growth for $2,869, reducing his holdings to 143,421 shares.

Expected impact

slight downward pressure as the market prices the insider sell

Evidence & confidence

The transaction size is trivial relative to market cap and typical daily volume; no broader implications.

Market effects

None; the sale does not affect the cannabis sector broadly.

None; the filing is specific to the company.

None

Counterpoint

The sale could be interpreted as a signal of insider concern, but the amount is too small to be meaningful.

Key entities

  • Canopy Growth Corp

    Canadian cannabis producer listed on NYSE under ticker CGC.

  • M. Shan Atkins

    Director of Canopy Growth who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.